Kornimate/medical-research-clean huggingface dataset:
safety and efficacy of rc-1291 hcl in patients with cancer related anorexia and weight loss

Conditions: Cancer Cachexia

Summary: anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. activation of ghrelin receptors have been demonstrated to stimulate appetite. rc-1291 hcl, by virtue of its ghrelin like activity and growth hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. this study will test the safety and efficacy of rc-1291 in the treatment of cancer patients with anorexia and weight loss.


Eligibility criteria:
inclusion criteria: * community-dwelling patients ≥ 18 years of age with incurable, histologically diagnosed cancer. * involuntary loss of body weight of ≥ 5 % within the past 6 months exclusion criteria: * presently hospitalized or in a nursing care facility. * inability to increase food intake from secondary causes. * liver disease * if female-pregnant, breast-feeding or of childbearing potential.

Keywords: anorexia cachexia
evaluation of meningococcal immune response among children who previously received menacwy conjugate vaccine

Conditions: Meningococcal Meningitis

Summary: the primary objective was to evaluate the persistence of bactericidal antibodies in children 40 and 60 months of age previously enrolled in the v59p14 (nct00474526) study who received novartis menacwy conjugate vaccine. the study also enrolled age-matched subjects who have never received any meningococcal vaccine (naïve subjects) to serve as a control group. in addition, the response of a booster dose at 60 months was evaluated.


Eligibility criteria:
inclusion criteria: * children eligible to be enrolled in the study are those whose parents provide written informed consent, and are in generally good health based on the clinical judgment of the investigators. * group 1 and 2 (follow up) subjects must be 40 +/- 3 months of age at the time of enrollment and participated in the original v59p14 study (nct00474526). * group 3 and 4 (naïve) subjects must be healthy, meningococcal vaccine-naïve children ages 40 +/- 3 months (group 3) or 60 +/-3 months (group 4) at the time of enrollment, respectively. exclusion criteria: * serious, acute, or chronic illnesses are reasons for exclusion. * subjects who have received any vaccine (excluding influenza vaccines) 28 days preceding enrollment visit. influenza vaccines (including flumist®) are excluded for the 14 days prior to the enrollment visit. * subjects who have received any meningococcal vaccine since birth (groups 3 \& 4 -naive) or last study dose in v59p14 (nct00474526) trial (groups 1 \& 2 - follow on).

Keywords: meningococcal acwy conjugate vaccine meningitis children persistence booster dose
mobile technology-based system for patient engagement and physician-directed remote management of heart failure

Conditions: Heart Failure

Summary: this pilot study is to assess the feasibility, preliminary utility and acceptance of a digital technology-based system for heart failure management.

heart failure continues to be a major public health problem. high-value, guideline-directed medical therapies (gdmt) for heart failure can reduce mortality and improve quality of life. however, large gaps in treatment with gdmt persist. while prior quality improvement efforts have focused on heart failure hospitalizations, there is a critical need to improve the quality-of-care post-discharge when the initiation and up-titration of gdmt is critical to optimizing outcomes. the main purpose of this pilot study is to assess the feasibility, preliminary utility and acceptance of a digital technology-based system for heart failure management.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * diagnosis of heart failure * most recent left ventricular ejection fraction ≤ 40% in the prior year based on echocardiogram, mri, ct, or nuclear perfusion * primary cardiologist enrolled in the study * currently admitted with upcoming discharge or discharged from hospital within the prior 2 weeks * at least two eligible heart failure therapies (guideline-recommended bb, rasi, mra, or sglt2i) not yet initiated or on ≤ 50% of target dose exclusion criteria: * receives dialysis * inotropic therapy during hospitalization * history of heart transplant or actively listed on heart transplant waiting list * history of left ventricular assist device implantation * cardiac amyloidosis * pregnant or currently trying to be pregnant * life expectancy estimated less than 6 months related to non-cardiac comorbidities as per investigator's judgement * actively enrolled in hospice or comfort care * currently participating in an investigational device or drug study or having participated in such a study within 30 days prior to screening * subject or their caregiver without a smartphone * subject or their caregiver not proficient with written and spoken english * subject unavailable to complete all study procedures (e.g., interviews) to the best of the subject and investigator's knowledge * any other disorder or condition that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion * subject has diminished decision-making capacity * planned discharge to skilled nursing facility

Keywords: heart failure digital health remote monitoring mobile application
an open label slv308 safety extension to study s308.3.001 in early pd patients

Conditions: Early Stage Parkinson's Disease

Summary: this is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind s308.3.001 trial


Eligibility criteria:
inclusion criteria: * patients who have completed s308.3.001 trial exclusion criteria: * patients with medically relevant abnormal findings (ecg, physical examination, aes) at end of the maintenance phase (visit m6, week 24) of study s308.3.001

Keywords: parkinson's disease
association between stroke and adrenal incidentalomas

Conditions: Stroke; Adrenal Incidentaloma

Summary: adrenal incidentalomas (ais) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. however, part of ais in patients is associated with stroke. stroke is a diseases which could cause of disability and death worldwide. in clinical practice, detailed information about the association between stroke and ais is not available. in this study, the investigators aimed to investigate the risk for disability and death in the large group of stroke patients with ais.

background: adrenal incidentalomas (ais) are commonly encountered in transsection imaging which purpose not for suspected adrenal disease. however, part of ais in patients is associated with stroke . the investigators aimed to investigate the risk for disability and death in the large group of stroke patients with ais. objective: to measure the association between stroke and levels of autonomous cortisol secretion in patients with ais. design: part 1, retrospective cohort study. from april 1, 2021, to september 30, 2021, cohort patients with stroke were recruited in this study. the investigators assess the standardised incidence rate of ais in all patients. meanwhile, detail information about stroke disease、patient and ais characteristics were record. part 2, prospective cohort study. from mar 1, 2022, to feb 29, 2024, cohort patients with stroke plane to recruit in this study. all patient receive the plasma cortisol level after a 1-mg dexamethasone suppression test. the investigators assess the standardised incidence rate of ais in all patients. meanwhile, detail information about stroke disease、patient and ais characteristics would be record.

Eligibility criteria:
inclusion criteria: * stroke disease , such as cerebral infarction、intracerebral hemorrhage and subarachnoid hemorrhage. exclusion criteria: * presence of metastatic cancer; * ais smaller than 1 cm; * nonadenoma lesions, such as myelolipomas,hemorrhages, and cysts; * oral glucocorticoid treatment with more than single doses in the past 3 months; * use of inhaled steroids or medication affecting dexamethasone metabolism; * systemic estrogen treatment.

Keywords: adrenal incidentaloma autonomous cortisol secretion stroke
the interaction of flavor with nicotine form in adult smokers

Conditions: Nicotine Dependence

Summary: this study seeks to elucidate the impact of e-cigarette flavor on subjective effects and nicotine exposure from e-cigarettes containing different forms of nicotine.


Eligibility criteria:
inclusion criteria: * at least 21 years old, able to read and write, use of combustible exclusion criteria: -
neurofeedback for treatment of central neuropathic pain (cnp) in sub-acute spinal cord injury (sci)

Conditions: Spinal Cord Injury

Summary: spinal cord injury (sci) affects a person's ability to move and feel sensation in the body. sci is also an indirect cause of a persistent pain, called central neuropathic pain (cnp). this pain typically develops several months after the injury. in 30-40% of sci patients, severe cnp affects their everyday living including sleep and mood. many patients give up work, not because of the injury, but because of pain. medical treatment of cnp is moderately effective and costly, both to the patient and to the health care system. in previous research, characteristic 'signatures' of brain waves that are probably related to cnp have been defined. based on this, a novel treatment for cnp based on neurofeedback was developed and clinically tested on five sci patients. electroencephalograph (eeg) was used to record patients' brain waves and these were shown to patients on a computer screen in a simple graphical form (e.g. bars). patients were trained to change their brain activity at will and, as a consequence, their pain was reduced. patients who had suffered from cnp for years received up to 40 neurofeedback treatment sessions, reducing their pain for several days after each session. the primary aim of this study is to apply neurofeedback therapy to a larger number of recently injured patients, who are still in a hospital. it is hypothesised that neurofeedback treatment will be more effective in people who have suffered from cnp for a shorter period of time. the secondary aim of the study is to define eeg predictors of cnp. eeg will be recorded in recently injured patients with no chronic pain, knowing that a certain number of patients will develop cnp within weeks or months. these patients will be followed up for a year and the eegs of patients who develop cnp will be compared with those who do not.


Eligibility criteria:
inclusion criteria: patients with central neuropathic pain (treatment and control groups) 1. normal or corrected to normal vision 2. no history of brain disease or injury 3. incomplete/complete spinal cord injury at level c5 to t12 4. below level neuropathic pain for at least 6 weeks 5. intensity of pain 4 or above (verbal numeric scale - vns) 6. stable medication regime responding to some extent to cnp medication treatment patients with no chronic pain 1. normal or corrected to normal vision 2. no history of brain disease or injury 3. incomplete/complete injury at level c5 to t12 4. within 23 months post-injury exclusion criteria: patients with central neuropathic pain (control and treatment groups) 1. chronic or acute muscular or visceral pain larger than 4 vns. 2. epilepsy 3. diagnosed mental health problems 4. active intervention of pain team patients with no chronic pain 1. chronic or acute pain larger than 3 on the vns. 2. epilepsy 3. diagnosed mental health problems
study evaluating the efficacy and safety of ipi 504 in patients with advanced dedifferentiated liposarcoma

Conditions: Dedifferentiated Liposarcoma

Summary: the primary objective of the study is to determine the safety profile and overall response rate of ipi 504 in patients with advanced dedifferentiated liposarcoma.


Eligibility criteria:
inclusion criteria: * at least 18 years of age at the time of signing informed consent. * histologic diagnosis of dedifferentiated liposarcoma. * available archival pathology specimen or tissue sample from a new biopsy for confirmation of diagnosis by central pathology reading. * at least one prior chemotherapy regimen for dedifferentiated liposarcoma. * no more than 2 prior chemotherapy regimens for dedifferentiated liposarcoma. note: any number of non-chemotherapy regimens is permitted. * measurable disease on computed tomography (ct) or magnetic resonance imaging (mri) as defined by recist (version 1.1) with at least one measurable lesion. * eastern cooperative oncology group (ecog) performance status: 0 or 1. * life expectancy ≥6 months. exclusion criteria: * prior treatment with any heat shock protein 90 (hsp90) inhibitor. * surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease * patients with prior hepatic resections or hepatic-directed therapy * use of a medication or food that is a clinically relevant cyp3a inhibitor or inducer within 2 weeks prior to dosing.
131i-rituximab for relapsed or refractory follicular or mantle cell lymphoma

Conditions: Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma

Summary: follicular lymphoma (fl) and mantle cell lymphoma (mcl) are rare lymphomas which consist of less than 5% of non-hodgkin lymphoma in korea. although fl with histologic grade 1 or 2 has relatively good prognosis, continual treatment is needed due to frequent relapse. fl with histologic grade 3 has poor prognosis similar to that of diffuse large b cell lymphoma. meanwhile, the response rate to systemic chemotherapy in mcl is low, so the treatment of relapsed mcl is challenging. so we investigate the efficacy of radioimmunotherapy using 131i-rituximab in refractory or relapsed patients with fl or mcl


Eligibility criteria:
inclusion criteria: * histologically confirmed follicular lymphoma or mantle cell lymphoma * relapsed or refractory patients * eastern cooperative oncology group performance status ≤ 2 * age≥ 20 years * more than one measurable lesion (more than 2cm sized lesion in conventional ct scan,more than 1cm sized lesion in spiral ct or contrast-enhanced pet/ct) * adequate renal function (serum creatinine ≤ 2.0 mg/dl or ccr ≥ 60 ml/min) * adequate hepatic function (serum bilirubin ≤ 2.0 mg/dl , ast/alt ≤ 3 upper normal limit) * adequate bone marrow reservoir (anc ≥1,500/㎕, platelet count≥ 75,000/㎕) * patient who agree the purpose and intention of this clinical trial exclusion criteria: * recent (\<5 years) history of other malignancy or unrecovered from the disease (appropriately treated skin cancer and uterine cervix carcinoma in situ are excluded) * hemodynamically unstable due to the recent (\<12 months) history of severe * heart disease such as myocardial infarction * acute complications of severe lung or metabolic disease * combined severe neurological or psychiatric disease * unrecovered from infection or other medical disease * recent (\<30 days) history of enrollment of other clinical trial * pregnant or breast-feeding woman * women of childbearing potential and men not employing adequate contraception at least for 1 year * previous history drug allergy to the content of 131i-rituximab * infection(sepsis, pneumonia, viral infection, etc) (inactivated hepatitis b carrier can be enrolled)
awareness of osteoporosis in patients with hyperthyroidism

Conditions: Hyperthyroidism; Osteoporosis; Osteoporosis Risk

Summary: osteoporosis is a condition that describes compromised skeletal microarchitecture in general, with clinical signs of decreased bone mineral density. multiple sclerosis patients are at increased risk for developing osteoporosis. identifying whether multiple sclerosis patients have information and awareness about this disease is crucial. this study is aimed to investigate awareness and knowledge of osteoporosis in patients with hyperthyroidism.

osteoporosis is a common disease of bone loss. the reduced bone strength predisposes an increased risk for fractures in older individuals. it can affect people from different ethnicity. many factors increase the risk of osteoporosis, including age, postmenopausal state, glucocorticoid use, low body weight calcium, vitamin d, immobility, and chronic inflammation. patients with hyperthyroidism are at high risk of developing osteoporosis due to chronic inflammation and their medications. patients' knowledge and awareness about osteoporosis are essential for early detection, implementation of lifestyle changes, and treatment compliance. this study aimed to investigate osteoporosis awareness and knowledge about osteoporosis in patients with multiple sclerosis.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hyperthyroidism * must be between the ages of 18 and 99 * must give consent to participate in the study exclusion criteria: • not giving consent
personalized functional profiling in metastatic gastrointestinal cancer or recurrent glioblastoma patients in luxembourg.

Conditions: Oncology

Summary: the investigators are developing a novel standardized and centralized approach named integrated personalized functional profiling (pfp) in luxembourg. based on recent improvements in cancer biopsy-derived 3d-culture technologies the pfp process will screen patient derived cells (pdcs) with fda/ema-approved drugs to generate personalized functional response profiles. the selected drug through pfp technology will provide personalized treatment recommendation for the patient. this pilot study will evaluate the clinical feasibility of setting-up an effective workflow as a first step. outcomes from this study will be used subsequently to help plan the clinical validation of the implementation of pfp.


Eligibility criteria:
inclusion criteria: * patient with recurrent glioblastoma (rgbm) or with metastatic gastrointestinal cancer (mgic), i.e. adenocarcinoma (any grade) of stomach, liver, pancreas, small intestine, colon, rectum * the patient has received previous cancer treatment for mgic or rgbm * male or female ≥ 18 years * life expectancy ≥ 12 weeks * histologically or cytologically confirmed diagnosis for mgic or recurrence of a glioblastoma, who grade iv * for women of childbearing potential, a negative pregnancy test documented prior to the screening visit is required * signed inform consent form before any study related procedure exclusion criteria: * for female patient, being pregnant, planning a pregnancy or breastfeeding * no fresh and viable tumor material available * known active human immunodeficiency virus (hiv), hepatitis b virus (hbv), or hepatitis c virus (hcv) infection * uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not allow compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol * in mgic arm, patient with non-adenocarcinoma gastrointestinal cancer * patient unable to understand and consent himself
fecal microbiota transplantation after autologous hsct in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the hypothesis of the study is that according to modern data, the pathogenesis of multiple sclerosis is inextricably linked to the patient's microbiota. therefore, transplantation of a normal fecal microbiota (fmt) can improve the outcome of autologous hematopoietic stem cell transplantation (autohsct) by increasing the disease-free period and disease progression suspension for at least 5 years after transplantation, which meets the neda (no evidence of disease activity) criteria, satisfying the current trends of clinical neurology.

autohsct may be a method of choice to treat patients with refractory forms of multiple sclerosis, taking into account the insufficient efficacy of first line therapy, lack of availability (government approval) and high cost of monoclonal antibodies as a second line drugs. in this setting, according to the safety-efficiency ratio the most appropriate are reduced intensity conditioning regimens in autohsct. in 75% of cases for refractory forms of multiple sclerosis it is possible to achieve 5 years remission with transplant mortality less than 1%. in recent years, it is quite clear that gut microbiota abnormalities may be one of mechanisms for autoimmune diseases development. therefore, the correction of gut dysbiosis through fmt from a healthy donor can improve the effectiveness of basic therapies. currently, fmt is a rapidly developing method of treating intestinal infections associated with multi-resistant bacteria, based on the replacement of the recipient's microbiota by the donor's microbiota.

Eligibility criteria:
inclusion criteria: * diagnosis: multiple sclerosis (relapsing-remitting, secondary-progressive, primary-progressive) * autohsct * signed informed consent * no second tumors * no severe concurrent illness * 1.0-6.5 points by edss * disease duration less than 20 years * disease progression on 1 and/or 2 line therapy (1 point edss 1.0-6.0 and 0,5 point edss 6.0-6.5) exclusion criteria: * moderate or severe cardiac dysfunction, left ventricular ejection fraction \<50% * moderate or severe decrease in pulmonary function, fev1 \<70% or dlco\<70% of predicted * respiratory distress \>grade i * severe organ dysfunction: ast or alt \>5 upper normal limits, bilirubin \>1.5 upper normal limits, creatinine \>2 upper normal limits * creatinine clearance \< 60 ml/min * uncontrolled bacterial or fungal infection at the time of enrollment * requirement for vasopressor support at the time of enrollment * karnofsky index \<30% * pregnancy * somatic or psychiatric disorder making the patient unable to sign informed consent
tranexamic acid and depot-medroxyprogesterone acetate for perimenopausal irregular uterine bleeding

Conditions: Uterine Bleeding

Summary: abnormal uterine bleeding is a symptom and not a disease. it is one of the most frequently encountered complaints in gynecologic practice. it accounts for more than 70% of all gynecological consultations in the peri- and post-menopausal age group. abnormal uterine bleeding may be acute or chronic and is defined as bleeding from the uterine corpus that is abnormal in regularity, volume, frequency, or duration and occurs in the absence of pregnancy. chronic heavy or prolonged uterine bleeding can result in anemia, interfere with daily activities. iron deficiency anemia develops in 21 to 67 percent of cases and raises concerns about uterine cancer. according to the international federation of obstetrics and gynecology, the classification of abnormal uterine bleeding is based on palm-coein which is an acronym for various etiologies namely polyp, adenomyosis, leiomyoma, malignancy and hyperplasia, coagulopathy, ovulatory dysfunction, endometrial disorders, iatrogenic and not otherwise classified (palm-coein).


Eligibility criteria:
inclusion criteria: * patients diagnosed, clinically as peri-menopausal abnormal uterine bleeding with normal pelvic examination. * patient's age ranging from 40- 55y. exclusion criteria: * post menopausal women * presence of fibroids, adenomyosis, polyp, adnexal mass, endometrial hyperplasia with atypia, and breast malignancy). * patients with uncontrolled hypertension. * patient of abnormal bleeding profile. * history of liver impairment and renal insufficiency * patients seeking for surgical management.